(4S)-5-azido-4-[(tert-butoxycarbonyl)amino]pentanoic acid | 475598-66-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S)-5-azido-4-[(tert-butoxycarbonyl)amino]pentanoic acid
• 英文别名: (4S)-5-azido-4-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid
• CAS: 475598-66-4
• 化学式: C₁₀H₁₈N₄O₄
• 分子量: 258.277
• InChiKey: FQDJKKSYVSVRKZ-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  90
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (4S)-5-azido-4-[(tert-butoxycarbonyl)amino]pentanoic acid 在 palladium on activated charcoal sodium tetrahydroborate 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 17.33h， 生成 {(S)-4-[3-((S)-4,5-Bis-tert-butoxycarbonylamino-pentanoylamino)-propylcarbamoyl]-2-tert-butoxycarbonylamino-butyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  手性n,n+1-二氨基酸的合成及其在树枝状大分子构建中的应用

  摘要：

  开发了从 l-谷氨酸开始合成手性 n,n+1-二氨基酸的有效方法。采用发散方法合成了以 1,3-丙二胺为核心，以 4,5-二氨基戊酸为支链单元的第二代原型氨基酸树枝状大分子。合成并表征了在外围用 n,n+1-二氨基酸修饰的二氨基丁烷聚 (丙烯亚胺) 树枝状大分子。

  DOI：

  10.1055/s-2002-33117
• 作为产物：
  描述：

  (S)-4-叔丁氧羰基氨基-5-羟基戊酸甲酯 在 sodium hydroxide 、 sodium azide 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 (4S)-5-azido-4-[(tert-butoxycarbonyl)amino]pentanoic acid
  参考文献：
  名称：

  手性n,n+1-二氨基酸的合成及其在树枝状大分子构建中的应用

  摘要：

  开发了从 l-谷氨酸开始合成手性 n,n+1-二氨基酸的有效方法。采用发散方法合成了以 1,3-丙二胺为核心，以 4,5-二氨基戊酸为支链单元的第二代原型氨基酸树枝状大分子。合成并表征了在外围用 n,n+1-二氨基酸修饰的二氨基丁烷聚 (丙烯亚胺) 树枝状大分子。

  DOI：

  10.1055/s-2002-33117

文献信息

• HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Albers Ronald J.

  公开号：US20090275564A1

  公开（公告）日：2009-11-05

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量氨基嘌呤化合物的组合物，以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者注射有效量的氨基嘌呤化合物。
• Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
  申请人：Albers J. Ronald

  公开号：US20070060598A1

  公开（公告）日：2007-03-15

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包括有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑退化、缺血再灌注损伤、疼痛和相关综合征、疾病相关消耗、石棉相关疾病、肺动脉高压或通过给需要治疗或预防JNK通路抑制的患者有效量的氨基嘌呤化合物进行治疗的方法。
• Methods of treatment and prevention using haloaryl substituted aminopurines
  申请人：Bennett L. Brydon

  公开号：US20080021048A1

  公开（公告）日：2008-01-24

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量的氨基嘌呤化合物的组合物以及用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或通过抑制JNK通路可治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF
  申请人：Albers Ronald J.

  公开号：US20090312320A1

  公开（公告）日：2009-12-17

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包含有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要的患者施用有效量的氨基嘌呤化合物。
• METHODS OF MODULATING INFLAMMATORY CELL RECRUITMENT AND GENE EXPRESSION USING HALOARYL SUBSTITUTED AMINOPURINES
  申请人：Bennett Brydon L.

  公开号：US20100249066A1

  公开（公告）日：2010-09-30

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包括有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者中施用有效量的氨基嘌呤化合物。